Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 5Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 7Genitourinary 5Lymphoid 2Gastrointestinal 2Sarcoma 1Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 1

Interventions

Cyclophosphamide 122Cytarabine 111fludarabine 90fludarabine phosphate 79Rituximab 75Azacitidine 74venetoclax 54Methotrexate 52Filgrastim 47Whole-Body Irradiation 45Busulfan 45Tacrolimus 35Etoposide 35Mycophenolic Acid 34Lenalidomide 32Antilymphocyte Serum 32Imatinib Mesylate 31Decitabine 31Granulocyte Colony-Stimulating Factor 30Peripheral Blood Stem Cell Transplantation 29Dexamethasone 29Cyclosporine 29Vincristine 26Melphalan 26Clofarabine 25Alemtuzumab 25Mitoxantrone 24Stem Cell Transplantation 22Radiotherapy 22Dasatinib 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Introns × Other hematologic neoplasm × Clear all
NCT04379518 2026-01-13

Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients

Roswell Park Cancer Institute

Phase 1/2 Terminated
4 enrolled 30 charts
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡